FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) filed by Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• TRILEPTAL (OXCARBAZEPINE)

Snippet

SUPPL AP for TRILEPTAL (OXCARBAZEPINE)